Preventing dementia by treating hypertension and preventing stroke

Hypertension

Volumn 44, Issue 1, 2004, Pages 20-21

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; VALSARTAN;

ALZHEIMER DISEASE; BRAIN ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG USE; EDITORIAL; HIPPOCAMPUS; HUMAN; HYPERTENSION; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; RISK FACTOR; STROKE; VASCULITIS;

AGED; ANTIHYPERTENSIVE AGENTS; ATROPHY; CEREBROVASCULAR ACCIDENT; DEMENTIA; HIPPOCAMPUS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 3042621503     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000132374.90924.2a     Document Type: Editorial

References (23)

1. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension. 2004;44:29-34.
2. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
3. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.
4. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci. 2003;72:1125-1133.
5. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia [see comments]. Lancet. 1996;347:1141-1145.
6. Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, Wolf PA. Dementia after stroke: the Framingham Study. Stroke. 2004.
7. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707-1712.
8. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
9. Forette F, Seux M-L, Staessen J, Thijs L, Birkenhäger WH, Babarskiene M-R, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352: 1347-1351.
10. Mogi N, Umegaki H, Hattori A, Maeda N, Miura H, Kuzuya M, Shimokata H, Ando F, Ito H, Iguchi A. Cognitive function in Japanese elderly with type 2 diabetes mellitus. J Diabetes Complications. 2004; 18:42-46.
11. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ. 2004;328:548.
12. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
13. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33:2351-2356.
14. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology. 2004;23:94-98.
15. Amarenco P, Lavallee P, Touboul PJ. Statins and stroke prevention. Cerebrovasc Dis. 2004;17 Suppl 1:81-88.
16. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, Welch MA, Zivin J; SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003;16: 389-395.
17. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
18. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
19. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699-702.
20. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21: 875-886.
21. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59:863-868.
22. Cargioli Vila MV, Carriquiry BF, Vargas CA. Dementia secondary to thalamic infarct: a case report. Rev Neurol. 2004;38:443-445.
23. Spence JD. Cerebral consequences of hypertension. In: Laragh JH, Brenner B, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1995: 741-753.